PVCT Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy
EN
05/10/2020

Underlying

PVCTProvectus Biopharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Provectus Biopharmaceuticals Inc

 PRESS RELEASE
Free
PVCT Provectus Bioph...

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alter...

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the University of Calgary’s Cumming School of Medicine in Human Vaccines & Immunotherapeutics. Their paper demonstrates that...

October 9, 2025 1 EN
 PRESS RELEASE
Free
PVCT Provectus Bioph...

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10...

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead investigational drug PV-10 in an orthotopic bladder cancer model. Results are expected in the first quarter of 2026. PV-10 is formulated from the Company’s pharmaceutical-grade rose bengal sodium active pharmaceutical ingredient. Conducted by Translational Drug Development, LLC (TD2), the study will evaluate P...

September 29, 2025 1 EN
 PRESS RELEASE
Free
PVCT Provectus Bioph...

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer C...

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt Cancer Center in Tampa, Florida (“Moffitt”), evaluating intratumoral PV-10 in models of head and neck squamous cell carcinoma (“HNSCC”). The study, published in Molecular Cancer Therapeutics, highlights novel mechanistic f...

June 26, 2025 1 EN
 PRESS RELEASE
Free
PVCT Provectus Bioph...

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annua...

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will also be accessible by Zoom Webinar. The meeting will be held on Wednesday, June 18, 2025, at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time. The webinar ...

June 9, 2025 1 EN
 PRESS RELEASE
Free
PVCT Provectus Bioph...

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Pr...

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc. (“VisiRose”), Provectus’s Founded Entity that is developing novel ocular therapeutics. VisiRose is a newly launched, privately held, clinical-stage biotechnology company focused on initially commercializing Rose Bengal Photodynamic Antimicrobial Therapy (“RB-PDAT”)...

January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch